TerminatedNCT05941442
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder
Medication studyAges 18–65United StatesAnxiety
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Phoenix and 30 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: July 31, 2023
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 80
- Sponsor
- AbbVie
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05941442
- Official title
Show the full official title
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Phoenix · Lafayette · Los Angeles
27 more locations
- Oceanside
- Orange
- Riverside
- San Jose
- Torrance
- Miami
- North Miami Beach
- Orlando
- Atlanta
- Decatur
- Savannah
- Elgin
- Overland Park
- Boston
- Las Vegas
- Berlin
- Brooklyn
- New York
- Rochester
- Staten Island
- Monroe
- Oklahoma City
- West Chester
- Austin
- DeSoto
- Draper
- Everett
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AbbVie.
Does this study involve medication?
Yes. The study involves medication, including Darigabat and Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as terminated.
